US Stock MarketDetailed Quotes
RLMD Relmada Therapeutics
- 0.470
- -0.011-2.33%
Close Dec 10 16:00 ET
- 0.458
- -0.012-2.47%
Pre 08:46 ET
14.18MMarket Cap-0.16P/E (TTM)
0.502High0.457Low1.75MVolume0.499Open0.481Pre Close824.20KTurnover6.35%Turnover RatioLossP/E (Static)30.17MShares7.22352wk High0.30P/B12.94MFloat Cap0.43252wk Low--Dividend TTM27.54MShs Float54.000Historical High--Div YieldTTM9.42%Amplitude0.432Historical Low0.471Avg Price1Lot Size
About Relmada Therapeutics Company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Company Profile
SymbolRLMD
Company NameRelmada Therapeutics
Listing DateOct 10, 2019
Issue Price0.00
Founded2012
CEODr. Sergio Traversa
MarketNASDAQ
Employees20
Fiscal Year Ends12-31
Address2222 Ponce de Leon Boulevard,3rd floor
CityCoral Gables
ProvinceFlorida
CountryUnited States of America
Zip Code33134
Phone1-786-629-1376
Websitehttp://www.relmada.com
Company Executives
- Name
- Position
- Salary
- Dr. Sergio Traversa
- Chief Executive Officer and Director
- 4.78M
- Maged Shenouda
- Chief Financial Officer and Principal Accounting Officer
- 2.34M
- Charles S. Ence
- Chief Accounting and Compliance Officer
- 2.33M
- Charles J. Casamento
- Chairman of the Board
- 674.90K
- Paul Kelly
- Independent Director
- 1.67M
- John Glasspool
- Independent Director
- 604.77K
- Fabiana Fedeli
- Independent Director
- 1.33M
Heat List
US
Overall
Symbol
Price
% Chg
No Data